| Description | Erianin is a nature product extracted from Dendrobium chrysotoxum, has notable antitumour activity , can cause extensive tumour necrosis, growth delay. Erianin has antiangiogenic action by inhibiting endothelial metabolism in a JNK/SAPK-dependent manner and inducing endothelial cytoskeletal disorganisation. Erianin shows potent inhibitory activity on the proliferation of HL-60 cells, the inhibition might be relative to the apoptosis induced by Erianin and the altered expression of bcl-2 and bax genes in HL-60 cells. |
| molecular weight | 318.36 |
| Molecular formula | C18H22O5 |
| CAS | 95041-90-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | Chloroform, Dichloromethane, Ethyl Acetate: Soluble DMSO: 57 mg/mL(179 mM) |
| References | 1. Lam F,et al. ZJU-6, a novel derivative of Erianin, shows potent anti-tubulin polymerisation and anti-angiogenic activities. Invest New Drugs. 2012 Oct;30(5):1899-907. 2. Zhou H,et al. Liquid chromatographic-mass spectrometry analysis and pharmacokinetic studies of erianin for intravenous injection in dogs. Arzneimittelforschung. 2009;59(3):141-5. |